Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy ...

New combination therapy of relacorilant and nab-paclitaxel shows promise in extending survival for patients with ...

Ovarian cancer survival rates are poorest for non-Hispanic white and Black women. Treatment is better than it used to be. But these advances haven’t equally boosted everyone’s survival rates.

A new drug is showing promise in tackling treatment-resistant ovarian cancer. Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve ...

Relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection Addition of relacorilant ...

Epithelial ovarian cancer is characterized by dissemination of tumors in the peritoneal cavity with a high risk of recurrence (75%, Stage III/IV) after surgery and chemotherapy.

Tackling ovarian cancer. Amit Kumar ... A three-year follow-up showed a median event-free survival of 29.5 months compared with 2.4 months ... and regulatory affairs to support and advance their ...

In the randomized, double-blind KEYNOTE-B96 trial (ClinicalTrials.gov Identifier: NCT05116189), study participants with platinum-resistant recurrent ovarian cancer (N=643) were randomly assigned ...